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Abstract: Tyrosine kinase inhibitors (TKIs) are molecules that compete with ATP on tyrosine kinase 
receptors (TKRs), blocking tyrosine kinase (TK) activation and then oncogenic pathways; they have 
been studied, and some of them are right approved for the treatment of many types of cancer. Among 
TKIs, one of the most explored chemical template is the pyrazolo[3,4-d]pyrimidine (PP) heterocyclic 
core, which proved to be a useful scaffold for the obtainment of effective compounds. Actually, 
derivatives belonging to this structural class show a large spectrum of activity, thus standing out as multi-target agents. 
Different PP compounds have been shown to act as: a) ABL inhibitors and antiproliferative agents against human 
leukemia cell lines; b) Src kinase inhibitors in neuroblastoma, medulloblastoma and osteosarcoma; c) Phospholipase D 
inhibitors in different neoplasias; d) Urokinase plasminogen activator inhibitors, in breast cancer. In thyroid cancer (TC), 
PP1 and PP2 (inhibitors of RET, Hck, lck, and fynT kinases, and a good inhibitor of c-Src and platelet-derived growth 
factor receptor) showed antineoplastic actvity in human papillary TC cell lines that carry spontaneous RET/PTC1 
rearrangements. More recently, new derivatives, (R)-1-phenethyl-N-(1-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
amine, namely, CLM3 and CLM29, have been demonstrated to exert a multiple signal transduction inhibition (including 
the RET-TK, BRAF, EGFR, and with antiangiogenic activity), showing antineoplastic activity, in vitro and in vivo, in 
papillary dedifferentiated, medullary and anaplastic TC. These data have shown the antineoplastic activity of PP in 
different neoplasias, opening the way to a future clinical evaluation in human cancers. 
Keywords: Antiangiogenic inhibitors, CLM29, CLM3, PP1, PP2, pyrazolo[3,4-d]pyrimidine, RET inhibitors, tyrosine kinase 
inhibitors.  
1. INTRODUCTION 
 In the last years several mutations and pathogenic 
mechanisms leading to onset of tumors, or their 
dedifferentation and resistance, were discovered. It was 
shown the cornerstone role of tyrosine kinases (TKs) and 
tyrosine kinase receptors (TKRs), like epidermal growth 
factor receptor (EGFR), vascular endothelial growth factor 
receptor (VEGFR), RET, BRAF, RAS/RAF/ERK and 
RAS/PI3K/AKT pathways, that are capable of causing cell 
transformations, giving mitogenic and survival signals, for 
example in thyroid cancer (TC) [1-6], and in other neoplasias 
[7-9].  
 Furthermore recently, it has been shown the importance 
of cytokines and chemokines [10] (usually involved in  
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autoimmune disorders [11, 12]) in tumorigenesis of TC [13-
15], and in other cancers [16, 17]. 
 TKs and TKRs are actually targets of new antineoplastic 
therapies. Tyrosine kinase inhibitors (TKIs) are molecules 
that compete with ATP on TKRs, blocking TK activation 
and then oncogenic pathways [18]. 
 Recently, some TKIs have been studied [1, 19-24], and 
some of them are right approved for the treatment of some 
types of cancer, as imatinib (for chronic myelogenous 
leukemia [25] and gastrointestinal stromal tumors [26]), 
sorafenib (for advanced renal cell carcinoma [27], advanced 
hepatocellular carcinoma [28], and radioactive iodine 
resistant advanced TC [29]), vandetanib and cabozantinib for 
medullary thyroid cancer (MTC) [30-33], and others [34]. 
 Among TKIs, pyrazolopyrimidines-derived compounds 
are produced and tested as useful antineoplastic agents. The 
pyrazolopyrimidines are constituted by a pyrazole ring  
fused with the pyrimidine moiety differently from the 
imidazole moiety in purines [35, 36]. At the beginning, 
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pyrazolopyrimidines were studied as adenosine receptor 
antagonists [37]. Different chemical compounds with 
pyrazolopyrimidines as central core were produced [38] and 
recently Mahajan et al. published a paper about ACK1-TK 
targeted cancer cells inhibition of proliferation, including 
pyrazolo[3,4-d]pyrimidines derivatives [39]. There are 
several isomeric forms of pyrazolopyrimidines with various 
mechanisms of action and possible purposes like antiviral 
[40], anticoccidials [41], antimicrobial [42-44], antitumor 
[45, 46], antileukemic [47], tuberculostatic [48], radioprotectant 
[49], and several other activities [50]. 
2. ANTINEOPLASTIC ACTIVITY 
 Pyrazolopyrimidines were evaluated against different 
targets as RET, VEGFR, EGFR, ABL, SRC, Aurora kinase, 
and others, each employed in the upset, progression and 
trasformation of many tumors.  
2.1. ABL Inhibitors 
 Manetti et al. [51] examined the role of the pyrazolo[3,4-
d]pyrimidines as ABL inhibitors and their antiproliferative 
action on human leukemia cell line. The effect of substituting 
different groups, as halogens and the hydrophobic regions of 
the ATP binding, was demonstrated by molecular modeling 
studies, showing its determinant activity on the affinity 
toward Abl. Pyrazolo[3,4-d]pyrimidines were produced by 
Radi et al. [52, 53] with an inhibitory effect in hypoxic 
human leukemia cells and the in vitro "absorption, 
distribution, metabolism, and excretion" (ADME) properties 
and metabolic activities were shown. The abovementioned 
molecules inhibited the Bcr-Abl kinase, increased caspase-3 
action and the cleavage of poly-ADP-ribose-polymerase. 
2.2. SRC Inhibitors  
 Tintori et al. [54] evaluated the antineoplastic activity 
against neuroblastoma cell proliferation. A subclass of 
nonreceptor TKs as target in the treatment of human cancers 
is the Src-family TKs. Among these, c-Src was found to 
stimulate cell proliferation, migration, and invasion as well 
as angiogenesis [55]. Hyperactivation of c-Src leads to 
aberrant cell activity that contributes to cancer development. 
Elevated expression levels of c-Src have been shown in 
different types of cancer and are associated with a poor 
prognosis with respect to overall survival. Moreover, recent 
studies suggest that c-Src could be associated with the 
development of acquired drug resistance [56]. 
 The antiproliferative and proapoptopic effects of 
pyrazolo[3,4-d]pyrimidines as Src kinase inhibitors in 
human osteosarcoma cells have been evaluated [57], 
concluding that they are capable in stimulating apoptosis and 
decreasing the Src phosphorylation. The inhibitory action of 
the compounds has been demonstrated to be dose dependent, 
via DNA damage or via increasing apoptosis. 
 New pyrazolo[3,4-d]pyrimidine derivatives as Src 
kinase inhibitors able to arrest cell cycle at G2/M phase and 
reduce growth of human medulloblastoma cells were 
produced [58]. 
2.3. Aurora Kinases Inhibitors 
 In 2012, 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines 
as dual inhibitors of Aurora kinases and CDK1 were 
synthesized [59] and the structure activity relationship 
(SAR) was reported, revealing to be particularly strong in 
case of low distribution volumes, elevated clearance rate, 
satisfying ADME properties, and thus demonstrating to be a 
good antitumor agent in leukemia cells. 
2.4. Phospholipase D (PLD) Inhibitors 
 PLD catalyzes the cleavage of phosphatidylcholine at the 
ester linkage–releasing choline and phosphatidic acid (PA) 
[60], that is a second lipid messenger belonging to different 
essential signaling and metabolic pathways [61], and is 
involved in the regulation of cellular functions mediating the 
enhancement of cell migration. The enhanced PLD activity 
and expression have been shown in different human cancer 
tissues [62-64]; PLD supports cells in initiating defence 
mechanisms, and its inhibition diminishes the ability of cells 
to adhere. Kulkarni et al. [65] evaluated the action of 
aminopyrazolopyrimidines, that have earlier been used as 
TKI [66] and dual inhibitors of tyrosine and 
phosphoinositide kinases [67], that were produced and used 
to initially screen the capability of purified bacterial PLD, 
strongly homologous to the human PLD. 
 These inhibitory molecules directly blocked enzyme/ 
vesicle substrate binding. Preliminary activity studies, 
performed by recombinant human PLDs in in vivo cell 
assays evaluating transphosphatidylation and head-group 
cleavage, showed inhibition in the mid- to low-nanomolar 
range in a physiological environment. 
2.5. Urokinase Plasminogen Activator (uPA) Inhibitors 
 uPA converts the circulating plasminogen to the active 
plasmin, is secreted as an inactive single-chain proenzyme 
by various cell types and is able to bind to a specific 
membrane uPA receptor (uPAR), in this way existing in a 
soluble or cell associated form [68]. uPA is involved in 
cancer invasion and metastasization, as members of the 
matrix metalloproteinases family, and takes part in many 
physiological functions [69]. After binding to uPAR, uPA 
initiates versatile intracellular signal pathways regulating cell 
proliferation, adhesion, and migration, interacting with 
different integrins and vitronectin [70]. Urokinase is 
involved in many malignancies, in lung, breast, cervix, 
bladder, kidney, brain, and stomach [71, 72]. The 
cytotoxicity of several compounds was tested using 
sulforhodamine B assay [73] in the breast cancer cell line 
MCF-7, the liver cancer cell line HepG2, and the lung 
carcinoma cell line A549. Shamroukh et al. [74] showed that 
pyrazole derivatives inhibit the activity of the urokinase 
enzyme, that is able to reduce cell proliferation leading to 
growth inhibition, and exerting an anti-carcinogenic activity 
in MCF-7 breast and HepG2 liver cancer cells. The SAR of 
the tested compounds showed that whereas substituted 
amino group enhanced the activity. However, fusining 
another ring (oxazine, pyrimidine, or fused pyrimidine) to 
the pyrazole structure decreased the anticancer activity. 
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2.6. Generation of Reactive Oxygen Species 
 The synthesis and anticancer activities of new 
pyrazolo[3,4-d]pyrimidine derivatives were evidenced by 
Rashad et al. [75] in 2011, as they generate reactive oxygen 
species (ROS) in human breast adenocarcinoma cells. Tumor 
cells are more sensitive than normal cells to the elevated 
levels of ROS present in cancer and increased by the 
supplementary oxidative stress created by anticancer agents, 
that causes injury to cellular components leading to cell 
death. The abovementioned compounds exert their antitumor 
effect partly owing to the production of H2O2. 
 The pyrazolo[3,4-d]pyrimidines have in vitro cytotoxic 
activity against breast adenocarcinoma [76] producing 
hydrogen peroxide and other free radicals leading to 
oxidative distress. The potency of pyrazolo[3,4-d]pyrimidines 
was higher that the one of pyrazole; anticancer activity was 
increased if the sulfonyl group was present between 
pyrazolo[3,4-d]pyrimidine and 4-chlorophenyl moiety. 
 Imine-pyrazolopyrimidinones have been reported as 
antitumoral agents [46], by multiple stress pathways in 
tumoral cells, as increased ROS levels, leading to DNA 
damage and topoisomerase II inhibition. Its binding 
interactions with topoisomerase II were investigated, 
showing knowledges about SAR and performing molecular 
modeling studies. 
2.7. PP1 and PP2 
 Dysregulation of RET signaling by oncogenic mutation, 
gene rearrangement, overexpression or transcriptional up-
regulation is involved in different human cancers (thyroid, 
breast, lung, etc) [77-83].  
 Carlomagno et al. [84] found that the 4-amino-5-(4-
methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1) 
inhibited RET-derived oncoproteins with a half maximal 
inhibitor concentration of 80 nM. Moreover, RET/PTC3-
transformed cells lost proliferative autonomy and showed 
morphological reversion if treated with 5 μM PP1. PP1 
inhibited the growth of two human papillary TC (PTC) cell 
lines, carrying spontaneously RET/PTC1 rearrangements, 
and stopped anchorage-independent growth and tumorigenicity 
in NIH3T3 fibroblasts from nude mice, expressing the 
RET/PTC3 oncogene. The obtained results showed that a 
new treatment strategy for RET-associated neoplasms could 
be targeting RET oncogenes using PP1 or related compounds. 
 Even if PP1 has a powerful growth inhibitory activity 
against human TC cell lines with RET/PTC rearrangements, 
it is not selective for RET, as it is a strong inhibitor also of 
lck, Hck, and fynT kinases, and a good inhibitor of c-Src and 
platelet-derived growth factor receptor (PDGFR) [85]. For 
this reason, besides to the direct effect on the RET kinase in 
vitro, indirect effects mediated in vivo by the inhibition of 
other kinases (particularly of c-Src, a crucial downstream 
RET effector) cannot be excluded [86]. If this hypothesis is 
correct, a single molecule could be used for “multiple-signal 
transduction therapy” of RET-dependent tumor formation. 
Furthermore, PP1 has been suggested to be also an inhibitor 
of PDGFR and c-Src, to prevent restenosis and vascular 
remodeling [87]. 
 Another pyrazolopyrimidine (PP2; 4-amino-5-(4-chloro-
phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) [88] is able to 
block the enzymatic activity of the isolated RET kinase and 
RET/PTC1 oncoprotein and the in vivo phosphorylation and 
signaling of the RET/PTC1 oncoprotein. PP2 inhibited the 
serum-independent growth of RET/PTC1-transformed 
NIH3T3 fibroblasts and of the two human PTC cell lines 
(TPC1 and FB2) harboring spontaneously RET/PTC1 
rearrangements. Moreover, PP2 stopped the potential of 
invasion of type I collagen matrix exerted by TPC1 cells. 
Therefore, pyrazolopyrimidines could be a good novel 
therapy for the treatment of human cancers supporting 
oncogenic activation of RET. 
2.8. CLM3, CLM29 and CLM94 
 Recently CLM3, (R)-1-phenethyl-N-(1-phenylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine, proposed for a multiple 
signal transduction inhibition (including the RET-TK, 
BRAF, EGFR, and with antiangiogenic activity) was 
disclosed. CLM3 showed an antiangiogenic effect with a less 
marked inhibitory activity on human TC cell lines, 
demonstrating time- and dose-dependent antiproliferative 
and proapoptotic effects on specific cell lines [89, 90]. 
 Sartini et al. [91] evaluated new derivatives of CLM3 in 
order that they completely comply with pharmacophore 
requirements of the ATP binding sites of VEGFR2 and RET. 
The new molecules were tested for their inhibitory properties 
against the target TKs and for their antiproliferative effect 
against endothelial and human TC cell lines, revealing a 
promising antiproliferative profile on endothelial and MTC 
cell lines. The tested compounds were more efficient against 
the target TC cell line TT, expressing mutated RET, with 
respect to the lead CLM3. 
 Moreover, the antitumor and antiangiogenic activities of 
the new ‘‘cyclic amide’’ compound CLM94 [92], as well as 
those of CLM3 [93] and CLM29 (a pyrazolo[3,4-
d]pyrimidine, that inhibits RET, EGFR, VEGFR, and has an 
anti-angiogenic activity) [89], have been demonstrated in 
primary anaplastic TC cells. Antonelli et al. showed that 
CLM3 and CLM29 inhibited the migration of papillary 
dedifferentiated thyroid cancer (DePTC) cells. The 
inhibitory effect of CLM3 and CLM29 was independent 
from the presence of V600EBRAF mutation. A DePTC cell 
line (AL), with V600EBRAF mutation, was produced, which 
was able to grow in nu/nu mice when inoculated sc. CLM3 
and CLM29 increased TSP-1 expression in the AL cell line. 
The antineoplastic activity of CLM3 and CLM29 may result 
from the combination of an antiproliferative effect associated 
with the increase of apoptosis in the tumoral cells and the 
inhibition of the migration and the neoplastic 
neovascularization. This last effect has been shown in vivo. 
In fact, a significant reduction of microvessels was observed 
in the CLM3-treated tumors. In addition, a significant 
decrease in the percentage of anti-VEGF antibody 
immunoreactivity in the tumor mass was also observed in the 
CLM3-treated group of animals. The mechanisms 
underlying the inhibition of the neoplastic neovascularization 
are probably related to the up-regulation of the main 
endogenous inhibitor of the angiogenesis, i.e. TSP-1; in fact, 
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CLM3 and CLM29 increased TSP-1 expression in the AL 
cell line. TSP-1 has many antiangiogenic effect: 1) inducing 
apoptosis of endothelial replicating cells [94]; and 2) 
interacting with many extracellular proteins involved in the 
angiogenic process, such as VEGF [95, 96]. 
 Ferrari et al. [97] reported the in vitro antineoplastic and 
antiangiogenic activities of CLM3 and CLM94 in primary 
cultures of MTC (pMTC) cells and the MTC cell line TT 
(harboring a RET C634W activating mutation) and MZ-
CRC-1 (carrying the MEN2B RET M918T mutation). These 
compounds inhibited the proliferation of TT and pMTC cells 
in vitro, in part by increasing the level of apoptosis. The 
inhibitory effect of CLM3 and CLM94 seemed to be 
independent from the presence of RET mutation in pMTC. 
These results are in agreement with the possibility that 
CLM3 and CLM94 seem to be inhibitors of multiple signal 
transduction pathways (including the RET-TK, EGFR, 
VEGFR) and have an anti-angiogenic effect. A significant 
decrease in the gene expression of VEGF-A was also 
observed in TT cells after CLM3 and CLM94 treatments. 
 More recently, CLM29 was tested in MTC, both in 
pMTC cells obtained at surgery, and in TT cells with the 
C634W RET mutation [98]. CLM29 (10, 30, 50 μM) 
inhibited significantly (P<0.001) the proliferation, and 
increased the percentage of apoptotic pMTC, TT and human 
dermal microvascular endothelial cells. The inhibition of 
proliferation by CLM29 was similar in pMTC cells 
with/without RET mutation. TT cells were injected sc in CD 
nu/nu mice, and tumor masses became detectable after 20-30 
days from xenotransplantation; CLM29 (50 mg/kg/die) 
reduced significantly tumor growth and weight, and 
microvessel density. These data showed the antineoplastic 
activity of CLM29 in MTC in vitro, and in vivo, opening the 
way to a future clinical evaluation [98]. 
CONCLUSION (Table 1) 
 TKIs are molecules that compete with ATP on TKRs, 
blocking TK activation and then oncogenic pathways; they 
have been studied, and some of them are right approved for 
the treatment of many types of cancer [99]. 
 Among TKIs, one of the most explored chemical 
template is the pyrazolo[3,4-d]pyrimidine (PP) heterocyclic 
core, which proved to be a useful scaffold for the obtainment 
of effective compounds. Actually, derivatives belonging to 
this structural class show a large spectrum of activity, thus 
standing out as multi-target agents. Different PP compounds 
have been shown to act as: a) ABL inhibitors and 
antiproliferative agents against human leukemia cell lines; b) 
Src kinase inhibitors in neuroblastoma, medulloblastoma and 
osteosarcoma; c) Phospholipase D inhibitors in different 
neoplasias; d) Urokinase plasminogen activator inhibitors, in 
breast cancer.  
 In TC, PP1 and PP2 (inhibitors of RET, Hck, lck, and 
fynT kinases, and a good inhibitor of c-Src and PDGFR) 
showed antineoplastic activity in human papillary TC cell 
lines carrying spontaneous RET/PTC1 rearrangements. More 
recently, the new derivatives, CLM3 and CLM29, have been 
demonstrated to exert a multiple signal transduction 
inhibition (including the RET-TK, BRAF, EGFR, and with 
antiangiogenic activity), showing antineoplastic activity, in 
vitro and in vivo, in papillary dedifferentiated, medullary and 
anaplastic TC. These data have shown the antineoplastic 
activity of PP in different neoplasias, opening the way to a 
future clinical evaluation in human cancers. 
 
Table 1. Key messages. 
1. 
The important role of tyrosine kinases (TKs) and tyrosine kinase 
receptors (TKRs) has been shown, that are capable of causing 
cell transformations, giving mitogenic and survival signals, in 
thyroid cancer (TC), and in other neoplasias. 
2. 
Tyrosine kinase inhibitors (TKIs) are molecules that compete 
with ATP on TKRs, blocking TK activation and then oncogenic 
pathways. 
3. 
Among TKIs, the pyrazolo[3,4-d]pyrimidine (PP) heterocyclic 
core is a useful scaffold for the obtainment of effective 
compounds, and derivatives belonging to this structural class 
show a large spectrum of activity, thus standing out as multi-
target agents. 
4. 
Different PP compounds have been shown to act as: a) ABL 
inhibitors and antiproliferative agents against human leukemia 
cell lines; b) Src kinase inhibitors in neuroblastoma, 
medulloblastoma and osteosarcoma; c) Phospholipase D 
inhibitors in different neoplasias; d) Urokinase plasminogen 
activator inhibitors, in breast cancer. 
5. 
In thyroid cancer (TC), PP1 and PP2 (inhibitors of RET, Hck, 
lck, and fynT kinases, and a good inhibitor of c-Src and PDGFR) 
showed antineoplastic activity in human papillary TC cell lines 
with spontaneous RET/PTC1 rearrangements. 
6. 
Recently, the new derivatives, CLM3 and CLM29, have been 
demonstrated to exert a multiple signal transduction inhibition 
(including the RET-TK, BRAF, EGFR, and with antiangiogenic 
activity), showing antineoplastic activity, in vitro and in vivo, in 
papillary dedifferentiated, medullary and anaplastic TC. 
 
LIST OF ABBREVIATIONS 
ADME = Absorption, distribution, metabolism, and 
excretion  
CLM3 = (R)-1-phenethyl-N-(1-phenylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine  
EGFR = Epidermal growth factor receptor  
MTC = Medullary thyroid cancer  
DePTC = Papillary dedifferentiated thyroid cancer  
PTC = Papillary thyroid cancer  
PA = Phosphatidic acid  
PLD = Phospholipase D  
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PDGFR = Platelet-derived growth factor receptor  
pMTC = Primary cultures of MTC  
PP = Pyrazolo[3,4-d]pyrimidine  
PP1 = 4-amino-5-(4-methylphenyl)-7-(t-butyl) 
pyrazolo[3,4-d]-pyrimidine  
PP2 = 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) 
pyrazolo[3,4-d]pyrimidine  
ROS = Reactive oxygen species  
SAR = Structure activity relationship  
TC = Thyroid cancer  
TKs = Tyrosine kinases  
TKIs = Tyrosine kinase inhibitors  
TKRs = Tyrosine kinase receptors  
uPA = Urokinase plasminogen activator  
uPAR = uPA receptor  
VEGFR = Vascular endothelial growth factor receptor  
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